MUC16 and ovarian cancer: Chekmasova’s team developed a range of CARs aimed at the extracellular domain of MUC16 (MUC-CD), resulting in T cells equipped with these CARs showing marked cytotoxicity against MUC-CD, thus effectively managing ovarian cancer (132).